XNASISPC
Market cap2mUSD
Dec 24, Last price
2.82USD
1D
0.71%
1Q
-45.45%
IPO
-98.12%
Name
iSpecimen Inc
Chart & Performance
P/E
—
P/S
0.27
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-36.10%
Rev. gr., 5y
17.70%
Revenues
10m
-4.56%
Net income
-11m
L+22.77%
CFO
-6m
L-0.17%
Earnings
May 22, 2025
Profile
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 9,928 -4.56% | 10,402 -6.58% | 11,135 36.06% | |||
Cost of revenue | 20,067 | 19,787 | 16,487 | |||
Unusual Expense (Income) | ||||||
NOPBT | (10,139) | (9,385) | (5,351) | |||
NOPBT Margin | ||||||
Operating Taxes | (1,205) | 1,054 | ||||
Tax Rate | ||||||
NOPAT | (10,139) | (8,180) | (6,405) | |||
Net income | (11,099) 22.77% | (9,041) -9.74% | (10,016) 48.20% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 71 | 6 | 41,497 | |||
BB yield | -1.57% | 0.00% | -3.04% | |||
| Debt | ||||||
Debt current | 334 | 158 | ||||
Long-term debt | 225 | 213 | 3,423 | |||
Deferred revenue | ||||||
Other long-term liabilities | (3,423) | |||||
Net debt | (4,446) | (14,937) | (24,316) | |||
| Cash flow | ||||||
Cash from operating activities | (5,808) | (5,818) | (10,668) | |||
CAPEX | (19) | (3,191) | (1,038) | |||
Cash from investing activities | (7,228) | (3,191) | (1,038) | |||
Cash from financing activities | 71 | (3,421) | 38,749 | |||
FCF | (9,806) | (6,098) | (15,141) | |||
| Balance | ||||||
Cash | 5,006 | 15,309 | 27,739 | |||
Long term investments | ||||||
Excess cash | 4,509 | 14,789 | 27,182 | |||
Stockholders' equity | (59,363) | (48,264) | (38,019) | |||
Invested Capital | 69,635 | 68,759 | 71,233 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 452 | 8,844 | 8,733 | |||
Price | 10.01 -63.59% | 27.50 -82.39% | 156.20 | |||
Market cap | 4,526 -98.14% | 243,218 -82.17% | 1,364,169 | |||
EV | 80 | 228,281 | 1,375,573 | |||
EBITDA | (8,024) | (8,180) | (4,347) | |||
EV/EBITDA | ||||||
Interest | 231 | 239 | 2,103 | |||
Interest/NOPBT | ||||||